

I. AMENDMENT

Amendment of the Claims:

The following listing of the claims replaces all previous listings or version of the claims:

Listing of the Claims

1. (Currently Amended) A method of inhibiting proliferation of multiple myeloma cells in vitro or in vivo, comprising the steps of: contacting said cells with ~~eureumin, wherein said eureumin~~ inhibits an amount of a curcuminoid effective to inhibit the proliferation of multiple myeloma cells.
2. (Currently Amended) A method of inducing apoptosis in multiple myeloma cells in vitro or in vivo, comprising the steps of: contacting said cells with ~~eureumin, wherein said eureumin~~ inhibits induces an amount of a curcuminoid effective to induce apoptosis in multiple myeloma cells.
3. (Withdrawn) A method of increasing the cytotoxic effects of one or more chemotherapeutic agent against multiple myeloma cells, comprising the steps of: contacting said cells with said one or more chemotherapeutic agent and ~~eureumin~~ a curcuminoid, wherein said ~~eureumin~~ curcuminoid increases the cytotoxic effects of said one or more chemotherapeutic agent against multiple myeloma cells.
4. (Withdrawn) The method of claim 3, wherein said one or more chemotherapeutic agent is

selected from the group consisting of vincristine, BCNU, melphalan, cyclophosphamide, Adriamycin, prednisone, velcade, thalidomide, and dexamethasone.

5. (Withdrawn) The method of claim 3, wherein said multiple myeloma cells are CD138.sup.+ plasma cells.

6. (Currently Amended) A method of treating multiple myeloma in an individual, comprising the step of administering ~~eureumin~~ a therapeutically effective amount of a curcuminoid to said individual.

7. (Currently Amended) The method of claim 6, wherein said ~~eureumin~~ curcuminoid is administered orally.

8. (Currently Amended) The method of claim 6, wherein said ~~eureumin~~ curcuminoid is administered in a dose of from about 0.01 mg/kg of the individual's body weight to about 500 mg/kg of the individual's body weight.

9. (Withdrawn) A method of increasing the cytotoxic effects of one or more chemotherapeutic agent against multiple myeloma cells in an individual, comprising the steps of: administering to said individual said one or more chemotherapeutic agent and ~~eureumin~~ a curcuminoid, wherein said ~~eureumin~~ curcuminoid increases the cytotoxic effects of said one or more chemotherapeutic agent against multiple myeloma cells in said individual.

10. (Withdrawn) The method of claim 9, wherein said one or more chemotherapeutic agent is selected from the group consisting of vincristine, BCNU, melphalan, cyclophosphamide, adriamycin, prednisone, velcade, thalidomide and dexamethasone.

11. (Withdrawn) The method of claim 9, wherein said ~~eureumin~~ curcuminoid is administered orally.

12. (Withdrawn) The method of claim 9, wherein said ~~eureumin~~ curcuminoid is administered in a dose of from about 0.01 mg/kg of the individual's body weight to about 500 mg/kg of the individual's body weight.

13. (Withdrawn) The method of claim 9, wherein said multiple myeloma cells are CD138.sup.+ plasma cells.